Tigenix says rheumatoid arthritis drug appears safe
BRUSSELS Dec 19 (Reuters) - Belgian stem cell research company Tigenix NV said on Wednesday that Cx611, its drug in development to treat rheumatoid arthritis, had produced positive interim safety results in a Phase IIa trial.
TiGenix said only two people in its 53-person study had suffered severe adverse effects and only one had discontinued treatment after three months. The study is set to run for six months and final results are due at the end of April 2013.
- Gaza fighting abates as diplomatic tension flares |
- Hague court orders Russia to pay over $50 billion in Yukos case
- Europe nervy as Russian assets hit by new sanctions talk
- Ukraine troops advance as experts renew attempt to reach crash site
- Pushing locals aside, Russians take top rebel posts in east Ukraine